Botulinum Type A Toxin in the Treatment of Lateral Canthal Lines (Crow's Feet)
A Phase II, Multi-Centre, Randomised, Double-blind, Dose-Ranging Study Comparing the Efficacy and Safety of a Single Treatment With 15, 30 or 45 Units (Per Eye) of Dysport to Placebo in the Symptomatic Treatment of Lateral Canthal Lines (Crow's Feet)
Sponsor: Ipsen
Listed as NCT00247559, this PHASE2 trial focuses on Lateral Canthal Lines and remains completed. Sponsored by Ipsen, it has been updated 8 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Sep 2019 — Dec 2019 [monthly]
Completed PHASE2
-
Jun 2018 — Sep 2019 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
May 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
For direct contact, visit the study record on ClinicalTrials.gov .